GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$170.68
+3.06%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$170.00
From 52W high+0.00%
Volume11.26M
Market cap$211.81B
P/E (TTM)—
P/S (TTM)6.8x
Div yield1.44%
Key dataOct 30, 2026
Open
$170.00
From 52W high
+0.00%
Volume
11.26M
Market cap
$211.81B
ValuationView details →
P/E (Fwd)
18.5x
EV/EBITDA
975.2x
P/E (TTM)
—
RSI (14)
75.5
MomentumView details →
1D Return
+3.06%
YTD Return
+40.53%
SummaryUpdated Sep 1, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Similar companies
Latest newsMore news →
GILEAD SCIENCES, INC. reported quarterly earnings of $2.55 per share, above the Zacks Consensus Estimate of $2.17 and compared with $2.47 per share a year earlier.3d agoGilead Sciences announced its third-quarter 2026 results of operations.3d agoGILEAD SCIENCES, INC. agreed to acquire an experimental immune disease drug from PepStar Therapeutics for nearly $1.3 billion in cash.6d ago